Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001295512 | SCV001484437 | uncertain significance | Bardet-Biedl syndrome | 2021-08-30 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with glutamine at codon 506 of the BBS2 protein (p.Arg506Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001835391 | SCV002089271 | uncertain significance | Bardet-Biedl syndrome 2 | 2021-10-14 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004733234 | SCV005355253 | uncertain significance | BBS2-related disorder | 2024-04-09 | no assertion criteria provided | clinical testing | The BBS2 c.1517G>A variant is predicted to result in the amino acid substitution p.Arg506Gln. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |